Sheryl A. Kluberg

Sheryl A. Kluberg

Auto-generated profile, based on publicly available information

Sheryl A. Kluberg

Department of Population Medicine Harvard Medical School and Harvard Pilgrim Health Care Institute Boston Massachusetts USA

Research Focus & Metrics

Academic Career Length

10Years (2017-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
16 December 2021 in Pharmacoepidemiology and Drug Safety
Verified
Journal Article
Open access
PDF file
SKSheryl A. Kluberg
Sheryl A. Kluberg
LHLaura Hou
Laura Hou
SDSarah K. Dutcher
Sarah K. Dutcher
MBMonisha Billings
Monisha Billings
BKBrian Kit
Brian Kit
NCNoelle Cocoros
Noelle Cocoros
Purpose: Health plan claims may provide complete longitudinal data for timely, real‐world population‐level COVID‐19 assessment. However, these data often lack laboratory results, the standard for COVID‐19 diagnosis.Methods: We assessed the validity of ICD‐10‐CM diagnosis codes for identifying patients hospitalized with COVID‐19 in U.S. claims databases, compared to linked laboratory results, among six Food and Drug Administration Sentinel System data partners (two large national insurers, four integrated delivery systems) from February 20–October 17, 2020. We identified patients hospitalized with COVID‐19 according to five ICD‐10‐CM diagnosis code‐based algorithms, which included combinations of codes U07.1, B97.29, general coronavirus codes, and diagnosis codes for severe symptoms. We calculated the positive predictive value (PPV) and sensitivity of each algorithm relative to laboratory test results. We stratified results by data source type and across three time periods: February 20–March 31 (Time A), April 1–30 (Time B), May 1–October 17 (Time C).Results: The five algorithms identified between 34 806 and 47 293 patients across the study periods; 23% with known laboratory results contributed to PPV calculations. PPVs were high and similar across algorithms. PPV of U07.1 alone was stable around 93% for integrated delivery systems, but declined over time from 93% to 70% among national insurers. Overall PPV of U07.1 across all data partners was 94.1% (95% CI, 92.3%–95.5%) in Time A and 81.2% (95% CI, 80.1%–82.2%) in Time C. Sensitivity was consistent across algorithms and over time, at 94.9% (95% CI, 94.2%–95.5%).Conclusion: Our results support the use of code U07.1 to identify hospitalized COVID‐19 patients in U.S. claims data.

1 December 2017 in Clinical Epidemiology
Verified
Journal Article
Open access
PDF file
KHKamban Hirasen
Kamban Hirasen
Denise H. EvansDenise H. Evans
Denise H. Evans
MMMhairi Maskew
Mhairi Maskew
ISIan M Sanne
Ian M Sanne
KSKate Shearer
Kate Shearer
MFMatthew P Fox
Matthew P Fox
Background: Long-term antiretroviral therapy (ART) adherence is critical for achieving optimal HIV treatment outcomes. Fixed-dose combination (FDC) single-pill regimens, introduced in South Africa in April 2013, has simplified pill taking. We evaluated treatment outcomes among patients initiated on a FDC compared to a similar multi-pill ART regimen in Johannesburg, South Africa. Methods: We conducted a retrospective cohort study of ART-naïve HIV-positive non-pregnant adult (≥18 years) patients without tuberculosis who initiated first-line ART on tenofovir and emtricitabine or lamivudine with efavirenz at Themba Lethu Clinic in Johannesburg, South Africa. We compared those initiated on a multi-pill ART regimen (3–5 pills/day; September 1, 2011–August 31, 2012) to those initiated on a FDC ART regimen (one pill/day; September 1, 2013–August 31, 2014). Treatment outcomes included attrition (combination of lost to follow-up and mortality), missed medical visits, and virologic suppression (viral load <400 copies/mL) by 12 months post-ART initiation. Cox proportional hazards models and Poisson regression were used to estimate the association between FDCs vs multiple pills and treatment outcomes. Results: We included 3151 patients in our analysis; 2230 (70.8%) patients initiated multi-pill ART and 921 (29.2%) patients initiated on a FDC. By 12 months post-initiation, attrition (adjusted hazard ratio: 0.98; 95% CI: 0.77–1.24) was similar across regimen types (FDC vs multi-pill). Although not significant, patients on a FDC were marginally more likely to achieve viral suppression by 6 (adjusted relative rate [aRR]: 1.10; 95% CI: 0.99–1.23) and 12 months (aRR: 1.12; 95% CI: 0.92–1.36) on ART. Patients initiated on a FDC were significantly less likely to miss medical visits during the first 12 months of treatment (aRR: 0.66; 95% CI: 0.52–0.83). Conclusion: Our results suggest FDCs may have a role to play in supporting patient adherence and medical monitoring through improved medical visit attendance. This may potentially improve treatment outcomes later on in treatment.

27 June 2018 in Tropical Medicine & International Health
Verified
Journal Article
Open access
PDF file
SKSheryl A. Kluberg
Sheryl A. Kluberg
MFMatthew P. Fox
Matthew P. Fox
MLMichael LaValley
Michael LaValley
DPDeenan Pillay
Deenan Pillay
TBTill Bärnighausen
Till Bärnighausen
JBJacob Bor
Jacob Bor
Objective: The 2015 WHO recommendation to initiate all HIV patients on antiretroviral therapy (ART) at diagnosis could potentially overextend health systems and crowd out sicker patients, mitigating the policy's impact. We evaluate whether South Africa's prior eligibility expansion from CD4 ≤ 200 to CD4 ≤ 350 cells/μl reduced ART uptake in the sickest patients.Methods: Using data on all patients presenting to the Hlabisa HIV Treatment and Care Programme in KwaZulu‐Natal from April 2010 to June 2012 (n = 13 809), we assessed the impact of the August 2011 eligibility expansion on the number of patients seeking care, number initiating ART and time from HIV diagnosis to ART initiation among patients always eligible (CD4 0–200), newly eligible (CD4 201–350) and not yet eligible by CD4 count (>350). We used interrupted time series methods to control for long‐run trends and isolate the effect of the policy.Results: Expanding ART eligibility led to an increased number of patients initiating ART per month [+95.5; 95% CI (−1.3; 192.3)]. Newly eligible patients (CD4 201–350) initiated treatment 47% faster than before (95% CI 19%; 82%), while the sickest patients (CD4 ≤ 200) saw no decline in the monthly number of patients initiating treatment or the rate of treatment uptake.Conclusion: The Hlabisa programme successfully extended ART to patients with CD4 ≤ 350 cells/μl, while ensuring that the sickest patients did not experience delays in ART initiation. Treatment programmes must be vigilant to maintain quality of care for the sickest as countries move to treat all patients irrespective of CD4 count.

27 February 2025 in Open Forum Infectious Diseases
Verified
Journal Article
Open access
SKSheryl A Kluberg
Sheryl A Kluberg
NCNoelle M Cocoros
Noelle M Cocoros
JOJune O’nEill
June O’nEill
TBThomas G Boyce
Thomas G Boyce
MSMaria E Sundaram
Maria E Sundaram
JSJames H Stark
James H Stark
Background: Lyme disease (LD) is the most common vector-borne disease in the United States, though traditional LD surveillance underestimates the burden of disease. We validated algorithms for early localized and disseminated LD, with and without LD-specific diagnosis codes, in states with high incidence and their neighboring states with low LD incidence. Methods: We identified cohorts of potential incident LD cases in administrative insurance claims data, October 2015—October 2023, in 1 national and 1 regional insurer. Three algorithms were studied: a primary algorithm of an LD-specific diagnosis code and indicated antibiotic and 2 secondary algorithms for disseminated LD requiring a non–LD-specific musculoskeletal or neurologic diagnosis code, an antibiotic, and an LD diagnostic test. We included individuals from high LD-incidence states and neighboring low LD-incidence states. We validated the algorithms using medical records for a sample of potential cases, classifying them according to modified surveillance case definitions. We calculated positive predictive values (PPVs) for each algorithm. Results: Overall, we identified 9483 potential LD cases in claims data and reviewed 841 medical records. The PPVs for the primary algorithm were 90.7% and 81.3% in high-incidence and neighboring states, respectively, when suspect, probable, and confirmed cases were included; they were 76.6% and 28.0% when only confirmed and probable were included. For confirmed and possible cases, the secondary musculoskeletal algorithm PPVs were 12.9% and 4.1%, and the secondary neurologic algorithm PPVs were 6.2% and 1.8% in high-incidence and neighboring states, respectively. Conclusions: This study found that claims-based algorithms requiring diagnosis codes for LD or for related symptoms, in addition to other criteria, can identify cohorts of true LD cases. These algorithms, adjusted for PPV, can be used to estimate LD incidence in the United States.

23 September 2025 in Infection Control & Hospital Epidemiology
Verified
Journal Article
Closed access
PDF file
SKSheryl A. Kluberg
Sheryl A. Kluberg
TCTom Chen
Tom Chen
RWRui Wang
Rui Wang
RJRobert Jin
Robert Jin
LDLaura DelloStritto
Laura DelloStritto
MKMichael Klompas
Michael Klompas
Objective: Non-ventilator hospital-acquired pneumonia (NV-HAP) is common and deadly. Guidelines recommend improving oral care and mobility performance to prevent NV-HAP but data on their impact are limited. We therefore evaluated associations between oral care and mobility performance with NV-HAP and mortality rates in a large hospital network. Design: Retrospective cohort study Setting: 144 acute care hospitals Patients: Adults hospitalized for ≥4 days between May 2021 and July 2023 Methods: We extracted daily data on oral care performance (yes, no) and patient mobility (bed-bound, upright, walking) and used time-varying Cox proportional hazards models to evaluate associations between oral care and mobility performance with NV-HAP and in-hospital mortality risk, adjusting for patients’ demographics, comorbidities, hospital service, daily vital signs, and daily laboratory measures. Results: Among 1,744,811 hospitalizations (9.6 million hospital-days), median patient age was 68 (IQR 55–78) and 50.6% were female. Persistent oral care for ≥3 days was associated with 16% less NV-HAP (hazard ratio (HR) 0.84; 95% CI: 0.82–0.86) and 6% lower mortality (HR 0.94; 95% CI: 0.92–0.96), with stronger effects in the ICU than outside the ICU. Persistent walking for ≥3 days was associated with 18% less NV-HAP (HR 0.82; 95% CI: 0.79–0.85) and 80% lower hospital-mortality (HR 0.20; 95% CI: 0.19–0.21), with stronger effects outside the ICU than in the ICU. Conclusions: In a large hospital network, both oral care and mobility were associated with lower risk of NV-HAP and hospital mortality, with differential effects inside and outside of the ICU. Prospective trials are needed to confirm these potential benefits.

10 August 2026 in medRxiv
Verified
Preprint
Open access
PDF file
SKSheryl A. Kluberg
Sheryl A. Kluberg
SWSarah J. Willis
Sarah J. Willis
JOJune O’Neill
June O’Neill
KSKatherine Shapiro
Katherine Shapiro
KCKevin Coughlin
Kevin Coughlin
NCNoelle Cocoros
Noelle Cocoros
Traditional surveillance underestimates Lyme disease (LD) incidence in the United States (US). We aimed to estimate national LD incidence using validated algorithms to identify LD cases in administrative claims data. We identified potential LD cases in commercial and Medicare claims, classified cases by disease stage, adjusted case counts using algorithm-specific positive predictive values, and standardized the adjusted counts to the US population. The study population included >66 million individuals per year. After adjustment and standardization, we estimated 191.7, 26.8, and 16.6 new cases per 100,000 population in high-incidence, neighboring, and low-incidence states, respectively, with 24% of cases diagnosed with disseminated disease. The relative burden of disseminated LD was highest in low-incidence states (28.6%) and increased with age. This study corroborates published estimates of national LD incidence and elucidates patterns of disease stage at diagnosis. The substantial burden of disseminated LD underscores the need for earlier detection and treatment of LD.